| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $55.3M | +29.6% |
| SG&A Expense | $18.0M | +48.0% |
| Operating Income | -$73.3M | -33.7% |
| Net Income | -$65.4M | -32.2% |
| EPS (Basic) | -$3.85 | +90.5% |
| EPS (Diluted) | -$3.85 | +90.5% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $26.6M | +12.2% |
| Short-term Investments | $125.5M | +29.3% |
| Current Assets | $154.4M | +24.3% |
| Total Assets | $206.4M | +58.9% |
| Current Liabilities | $8.1M | -13.1% |
| Total Liabilities | $55.8M | +495.9% |
| Stockholders' Equity | $150.6M | +218.5% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$60.8M | -29.8% |
| Capital Expenditures | $2.5M | +300.6% |
| Investing Cash Flow | -$26.1M | +31.8% |
| Financing Cash Flow | $89.8M | -8.2% |
| Free Cash Flow | -$63.4M | -33.5% |